Arrhythmias & electrophysiology
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation: Navigating Heterogeneity in Clinical Evidence: JACC Evidence Review
Authors' conclusion
For most anticoagulation-eligible patients, anticoagulation remains the preferred first-line strategy. LAAC is a reasonable option when long-term anticoagulation is unsafe or unsustainable provided that procedural risk, adjunct antithrombotic feasibility, surveillance needs, and competing mortality are carefully considered. RCT evidence in this latter population is limited, and RCTs in other populations have features that limit their support for LAAC as an alternative to anticoagulation. Because LAAC and anticoagulation offer different types of risk, aligning the most applicable evidence with patient values through shared decision-making is central to care.
Study context
- Population
- Selected patients with atrial fibrillation (AF)
- Participants
- >7,000 patients
- Comparison
- Left atrial appendage closure (LAAC) as an alternative to long-term anticoagulation for preventing stroke or systemic embolism
- Outcome
- Interpretation of the major randomized controlled trials (RCTs) (OPTION, CLOSURE-AF, CHAMPION-AF)
Main finding
As reported in the abstract
- Trials are not one coherent evidence base; they differ in patient phenotype, comparator, device generation, postprocedure antithrombotic regimen, endpoint construction, and follow-up duration
- Patient eligibility as well as thromboembolic and bleeding risk varied markedly across trials
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →